A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: Does resistance testing pay off?

Antiviral Therapy

Volumn 11, Issue 3, 2006, Pages 305-314

  Simcock, Mathew ^a,b   Sendi, Pedram ^a,b   Ledergerber, Bruno ^c   Keller, Tamara ^c   Schüpbach, Jörg ^d   Battegay, Manuel ^a   Günthard, Huldrych F ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; FEMALE; GENOTYPE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; SWITZERLAND; TERTIARY HEALTH CARE; TREATMENT FAILURE; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS; TREATMENT FAILURE;

EID: 33744735992     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). BETA 1997; 11-22.
2. Aceti A, Carosi G. Genotypic resistance tests in the management of the HIV-infected patient at virological failure. Scand J Infect Dis Suppl 2003; 35 Suppl 106:61-66.
3. Blum RA, Wylie N, England T, French C. HIV resistance testing in the USA - a model for the application of pharmacogenomics in the clinical setting. Pharmacogenomics. 2005; 6:169-179.
4. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS 2001; 15:309-320.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-2426.
6. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
7. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-848.
8. Chaix C, Grenier-Sennelier C, Clevenbergh P, et al. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J Acquir Immune Defic Syndr 2000; 24:227-231.
9. Corzillius M, Muhlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir Ther 2004; 9:27-36.
10. Lauria EN, Angeletti C. Cost-effectiveness analysis of using antiretroviral drug resistance testing. Scand J Infect Dis Suppl 2003; 35 Suppl 106:54-57.
11. Weinstein MC, Goldie SI, Losina E, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-450.
12. Dean GL, Fisher M, Loveday C. HIV drug-resistance testing on archived samples to help current clinical decisions. AIDS 2000; 14:208-209.
13. Stephenson J. HIV drug resistance testing shows promise. JAMA 1999; 281:309-310.
14. Panidou ET, Trikalinos TA, Ioannidis JP. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 2004; 18:2153-2161.
15. Haupts S, Ledergerber B, Boni J, et al. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir Ther 2003; 8:443-454.
16. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39:387-394.
17. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6:217-227.
18. Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. J Eval Clin Pract 1999; 5:283-295.
19. Mracna M, Becker-Pergola G, Dileanis J, et al. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol 2001; 39:4323-4327.
20. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinayir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-8276.
21. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
22. Drummond MF, O'Brian B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes. New York: Oxford University Press USA; 2005.
23. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. Health Econ 2003; 12:377-392.
24. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14:763-776.
25. Rubin DB. Inference and missing data. Biometrika 1976; 63:581-592.
26. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
27. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.